Hormonal
Mitochondrial dysfunction in adipose tissue, characterized by reduced oxidative capacity and increased ROS, is a primary driver of insulin resistance and metabolic disease.
Maintaining healthy mitochondrial function in fat cells is crucial for managing insulin sensitivity and preventing metabolic diseases. Strategies to support this include regular exercise, caloric restriction, and potentially specific dietary compounds or medications that target mitochondrial health, as these can improve the body's ability to regulate glucose and lipids.
Mitochondrial dysfunction in adipocytes has been reported to have strong correlation with metabolic diseases, including obesity and type 2 diabetes. Dysfunction of mitochondria results in detrimental effects on adipocyte differentiation, lipid metabolism, insulin sensitivity, oxidative capacity, and thermogenesis, which consequently lead to metabolic diseases.
Why this rating
The paper is a review citing multiple human and animal studies showing consistent correlations between mitochondrial dysfunction and metabolic disease.
Source
The Role of Adipose Tissue Mitochondria: Regulation of Mitochondrial Function for the Treatment of Metabolic Diseases
Jae Ho Lee et al. · International Journal of Molecular Sciences · 2019
DOI 10.3390/ijms20194924
More from this paper
- Activation of brown adipose tissue (BAT) thermogenesis and white adipose tissue (WAT) browning through UCP1 activation improves insulin sensitivity and energy expenditure.Good
- Exercise induces WAT browning via the myokine Irisin, leading to increased energy expenditure and improved insulin sensitivity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →